Lipocine has patented a method for testosterone replacement therapy in hypogonadal males. The untitrated dose regimen with a non-undecanoate testosterone ester aims to treat conditions like fatigue and muscle size reduction. The oral administration with food eliminates the need for dose adjustments. GlobalData’s report on Lipocine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lipocine, Nanoparticle drug conjugates was a key innovation area identified from patents. Lipocine's grant share as of May 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11992496B1) outlines a method for treating conditions related to fatigue, reduction in muscle size, and muscle strength by orally administering a pharmaceutical composition containing a non-undecanoate testosterone ester in an untitrated dose regimen with food. The method involves providing a total daily dose of the testosterone ester within specific ranges, ranging from a minimum of about 375 mg to a maximum of about 1150 mg, and administering the composition at least once daily. The composition can be in various forms such as capsules, tablets, powders, or suspensions, and includes additives to enhance its effectiveness.
Furthermore, the patent describes a pharmaceutical composition comprising a non-undecanoate testosterone ester, pharmaceutically acceptable carriers, and additives, with the testosterone ester constituting about 15%-45% of the composition. This composition, when administered to individuals with the specified conditions, aims to improve or prevent further deterioration in fatigue, muscle size, and strength. The composition includes various surfactants, solidifying agents, and fatty acids to enhance its properties. Additionally, the administration regimen includes specific dosage ranges, daily administration, and the option to discontinue therapy if serum testosterone levels exceed a certain threshold. The composition can be administered with or without food, with the food having a specified fat content, and is intended for both eugonadal and hypogonadal subjects to maintain serum testosterone levels within a normal range for a majority of the population with the conditions mentioned.
To know more about GlobalData’s detailed insights on Lipocine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
